Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Pancreatic Neoplasms
Interventions
BIOLOGICAL

MV

MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.

OTHER

Standard Treatment

Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.

Trial Locations (1)

510000

Biological treatment center in Fuda cancer hospital, Guangzhou

All Listed Sponsors
lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT02338752 - Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient | Biotech Hunter | Biotech Hunter